Do We Still Need Aspirin in Coronary Artery Disease?
Aspirin has for some time been used as a first-line treatment for acute coronary syndromes, including ST-elevation myocardial infarction, for secondary prevention of established coronary disease, and for primary prevention in patients at risk of coronary artery disease. Although aspirin has been in...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/24/7534 |
| _version_ | 1797380519794573312 |
|---|---|
| author | Muhammad Haisum Maqsood Glenn N. Levine Neal D. Kleiman David Hasdai Barry F. Uretsky Yochai Birnbaum |
| author_facet | Muhammad Haisum Maqsood Glenn N. Levine Neal D. Kleiman David Hasdai Barry F. Uretsky Yochai Birnbaum |
| author_sort | Muhammad Haisum Maqsood |
| collection | DOAJ |
| description | Aspirin has for some time been used as a first-line treatment for acute coronary syndromes, including ST-elevation myocardial infarction, for secondary prevention of established coronary disease, and for primary prevention in patients at risk of coronary artery disease. Although aspirin has been in use for decades, the available evidence for its efficacy largely predates the introduction of other drugs, such as statins and P2Y12 inhibitors. Based on recent trials, the recommendation for aspirin use as primary prevention has been downgraded. In addition, P2Y12 inhibitors given as a single antiplatelet therapy have been associated with a lower incidence of bleeding than dual antiplatelet therapy in combination with aspirin in patients with stable and unstable coronary artery disease. The aim of this review is to discuss the role of aspirin considering the available evidence for primary prevention, secondary prevention for stable coronary artery disease or acute coronary syndromes, and after percutaneous coronary intervention or coronary artery bypass revascularization. |
| first_indexed | 2024-03-08T20:39:27Z |
| format | Article |
| id | doaj.art-05f7087982b141bd8b40087a4e5bb8f2 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T20:39:27Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-05f7087982b141bd8b40087a4e5bb8f22023-12-22T14:16:53ZengMDPI AGJournal of Clinical Medicine2077-03832023-12-011224753410.3390/jcm12247534Do We Still Need Aspirin in Coronary Artery Disease?Muhammad Haisum Maqsood0Glenn N. Levine1Neal D. Kleiman2David Hasdai3Barry F. Uretsky4Yochai Birnbaum5Department of Cardiology, DeBakey Heart and Vascular Center, Methodist Hospital, Houston, TX 77030, USAThe Section of Cardiology, Baylor College of Medicine, Houston, TX 77030, USADepartment of Cardiology, Section of Interventional Cardiology, Houston Methodist DeBakey Heart Center, Houston, TX 77030, USADepartment of Cardiology, Rabin Medical Center, Tel Aviv University, Petah Tikva 49200, IsraelCentral Arkansas Veterans Health System, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USAThe Section of Cardiology, Baylor College of Medicine, Houston, TX 77030, USAAspirin has for some time been used as a first-line treatment for acute coronary syndromes, including ST-elevation myocardial infarction, for secondary prevention of established coronary disease, and for primary prevention in patients at risk of coronary artery disease. Although aspirin has been in use for decades, the available evidence for its efficacy largely predates the introduction of other drugs, such as statins and P2Y12 inhibitors. Based on recent trials, the recommendation for aspirin use as primary prevention has been downgraded. In addition, P2Y12 inhibitors given as a single antiplatelet therapy have been associated with a lower incidence of bleeding than dual antiplatelet therapy in combination with aspirin in patients with stable and unstable coronary artery disease. The aim of this review is to discuss the role of aspirin considering the available evidence for primary prevention, secondary prevention for stable coronary artery disease or acute coronary syndromes, and after percutaneous coronary intervention or coronary artery bypass revascularization.https://www.mdpi.com/2077-0383/12/24/7534acute coronary syndromeaspirinclopidogrelP2Y12 inhibitorspercutaneous coronary interventionprimary prevention |
| spellingShingle | Muhammad Haisum Maqsood Glenn N. Levine Neal D. Kleiman David Hasdai Barry F. Uretsky Yochai Birnbaum Do We Still Need Aspirin in Coronary Artery Disease? Journal of Clinical Medicine acute coronary syndrome aspirin clopidogrel P2Y12 inhibitors percutaneous coronary intervention primary prevention |
| title | Do We Still Need Aspirin in Coronary Artery Disease? |
| title_full | Do We Still Need Aspirin in Coronary Artery Disease? |
| title_fullStr | Do We Still Need Aspirin in Coronary Artery Disease? |
| title_full_unstemmed | Do We Still Need Aspirin in Coronary Artery Disease? |
| title_short | Do We Still Need Aspirin in Coronary Artery Disease? |
| title_sort | do we still need aspirin in coronary artery disease |
| topic | acute coronary syndrome aspirin clopidogrel P2Y12 inhibitors percutaneous coronary intervention primary prevention |
| url | https://www.mdpi.com/2077-0383/12/24/7534 |
| work_keys_str_mv | AT muhammadhaisummaqsood dowestillneedaspirinincoronaryarterydisease AT glennnlevine dowestillneedaspirinincoronaryarterydisease AT nealdkleiman dowestillneedaspirinincoronaryarterydisease AT davidhasdai dowestillneedaspirinincoronaryarterydisease AT barryfuretsky dowestillneedaspirinincoronaryarterydisease AT yochaibirnbaum dowestillneedaspirinincoronaryarterydisease |